| CRINETICS PHARM. DL-,001 |
| USA |
| Gesundheit |
| US22663K1079 / A2JQTJ |
| 6Z4 (Frankfurt) / CRNX (NASDAQ) |
| FRA:6Z4, ETR:6Z4, 6Z4:GR, NASDAQ:CRNX |
| - |
| https://www.crinetics.com.. |
|
Crinetics Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small-molecule therapeutics for rare endocrine diseases and endocrine-related tumors. Its proprietary p..
>Volltext.. |
| 3317.18 Mio. EUR |
| 2483.73 Mio. EUR |
| 6.67 Mio. EUR |
| -444.31 Mio. EUR |
| -403.11 Mio. EUR |
| -4.28 EUR |
| 42.05 Mio. EUR |
| 87.96 Mio. EUR |
| -327.4 Mio. EUR |
| 12.08 |
| - |
| -37.44% |
| - |
| - |
| - |
| CRINETICS |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|